This Week in Cancer Discovery

Premium

In Cancer Discovery, a team of US researchers reports a first-in-human trial of a STAT3 decoy oligonucleotide in patients with head and neck tumors. Transcription factors like STAT3 have been considered undruggable, the team says. For this study, the researchers developed a decoy targeting STAT3 and performed a phase 0 trial in which they injected it into patients with head and neck cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.